Audrey Gros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Audrey Gros has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Philippe Merlio
University of Bordeaux
6 shared publications - Anne Pham-Ledard
Service de Dermatologie, CHU de Bordeaux BoRdeaux Institute of Oncology, BRIC INSERM U1312, INSERM BoRdeaux Institute of onCology, Team 5, Université de Bordeaux Bordeaux France
4 shared publications - Sandrine Poglio
Bordeaux Institute of Oncology, Unité Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France
4 shared publications Marie Beylot-Barry
Univ. Bordeaux, INSERM, BaRITOn, U1053, Bordeaux, France
3 shared publications- Marie Beylot-Barry
Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
3 shared publications Anne Pham-Ledard
Univ. Bordeaux, INSERM, BaRITOn, U1053, Bordeaux, France
2 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 850-863
Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type (PCDLBCL-LT) is a rare subset of DLBCL that exhibits genetic features shared with LBCL of immune-privileged sites (notably the MYD88L265P mutation) and is enriched in tumor-associated macrophages expressing M2 markers. Using a unique PCDLBCL-LT cell line (ARSI cell line) developed in our institute, we sought to mechanistically decipher the interplay between lymphoma cells and macrophages. We demonstrate that ARSI cells induce phenotypic, transcriptional, and functional changes in macrophages obtained from primary monocytes and THP-1 cell line. These changes do not require cell-cell contact, and proteome analysis of ARSI secretome reveals high concentration of several cytokines and chemokines known to affect macrophages, including interleukin-10 (IL-10). We then demonstrate that IL-10/Interleukin 10 receptor subunit alpha (IL-10RA) interaction blockade inhibits macrophage polarization induced by tumor cells. These findings are reproduced when macrophages are cocultured with PCDLBCL-LT cells from different patient-derived xenografts. However, among 4 other DLBCL cell lines, only the MYD88-mutated OCI-Ly3 cell line exhibits similar effects, which highlights the variability of macrophage interplays and led us to hypothesize that macrophage shaping, beyond the cutaneous localization, may rely on specific genetics of tumor cells. Finally, we reveal that macrophages enhance tumor cell proliferation and promote resistance to doxorubicin in coculture. In conclusion, these results confirm the robustness of this model to study lymphoma cell and macrophage interplays, underline the critical role of IL-10 in lymphoma microenvironment modeling, and may contribute to better defining its specificities in an era of rising microenvironment-targeted therapies.
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 850-863
Open AccessCutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type (PCDLBCL-LT) is a rare subset of DLBCL that exhibits genetic features shared with LBCL of immune-privileged sites (notably the MYD88L265P mutation) and is enriched in tumor-associated macrophages expressing M2 markers. Using a unique PCDLBCL-LT cell line (ARSI cell line) developed in our institute, we sought to mechanistically decipher the interplay between lymphoma cells and macrophages. We demonstrate that ARSI cells induce phenotypic, transcriptional, and functional changes in macrophages obtained from primary monocytes and THP-1 cell line. These changes do not require cell-cell contact, and proteome analysis of ARSI secretome reveals high concentration of several cytokines and chemokines known to affect macrophages, including interleukin-10 (IL-10). We then demonstrate that IL-10/Interleukin 10 receptor subunit alpha (IL-10RA) interaction blockade inhibits macrophage polarization induced by tumor cells. These findings are reproduced when macrophages are cocultured with PCDLBCL-LT cells from different patient-derived xenografts. However, among 4 other DLBCL cell lines, only the MYD88-mutated OCI-Ly3 cell line exhibits similar effects, which highlights the variability of macrophage interplays and led us to hypothesize that macrophage shaping, beyond the cutaneous localization, may rely on specific genetics of tumor cells. Finally, we reveal that macrophages enhance tumor cell proliferation and promote resistance to doxorubicin in coculture. In conclusion, these results confirm the robustness of this model to study lymphoma cell and macrophage interplays, underline the critical role of IL-10 in lymphoma microenvironment modeling, and may contribute to better defining its specificities in an era of rising microenvironment-targeted therapies.
- 21 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1326-1329.e5
Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma–Leg Type
- 21 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1326-1329.e5
Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma–Leg Type
- Open Access
- 6 September 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (2) , 340-344.e6
Patient-Derived Xenograft and Cell Line Models of Human Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type
- 6 September 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (2) , 340-344.e6
Open AccessPatient-Derived Xenograft and Cell Line Models of Human Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type
- 24 February 2022
- Published by Elsevier in Cancer Genetics
- Vol. 264-265, 8-15
PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas
- 24 February 2022
- Published by Elsevier in Cancer Genetics
- Vol. 264-265, 8-15
PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas
- Open Access
- 21 October 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (16) , 1384-1386
Single-cell trajectories in Sézary syndrome
In this issue of Blood, Herrera et al1 identified a restricted phylogeny together with a proliferation and T-cell activation signature in the skin compartment o
- 21 October 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (16) , 1384-1386
Open AccessSingle-cell trajectories in Sézary syndrome
In this issue of Blood, Herrera et al1 identified a restricted phylogeny together with a proliferation and T-cell activation signature in the skin compartment o
- Open Access
- 26 October 2020
- Published by Springer Nature in Leukemia
- Vol. 35 (6) , 1696-1709
Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity
Sézary Syndrome (SS) is a rare aggressive epidermotropic cutaneous T-cell lymphoma (CTCL) defined by erythroderma, pruritis, and a circulating atypical CD4 + T-cell clonal population. The diversity of Sézary cell (SC) phenotype and genotype may reflect either plasticity or heterogeneity, which was difficult to evaluate dynamically until the achievement of long-term SC expansion. Therefore, we developed six defined culture conditions allowing for the expansion of SC defined by their phenotype and monoclonality in four of seven SS cases. Engraftment of SC through the intrafemoral route into immunodeficient NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ (NSG) mice was achieved in 2 of 14 SS cases. Secondary xenograft by percutaneous injection mimicked most of the features of SS with dermal infiltration, epidermotropism, and blood spreading. These models also allowed assessing the intra-individual heterogeneity of patient SC. Subclones sharing the same TCR gene rearrangement evolved independently according to culture conditions and/or after xenografting. This clonal selection was associated with some immunophenotypic plasticity and limited genomic evolution both in vitro and in vivo. The long-term amplification of SC allowed us to develop eight new SC lines derived from four different patients. These lines represent the cell of origin diversity of SC and provide new tools to evaluate their functional hallmarks and response to therapy.
- 26 October 2020
- Published by Springer Nature in Leukemia
- Vol. 35 (6) , 1696-1709
Open AccessXenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity
Sézary Syndrome (SS) is a rare aggressive epidermotropic cutaneous T-cell lymphoma (CTCL) defined by erythroderma, pruritis, and a circulating atypical CD4 + T-cell clonal population. The diversity of Sézary cell (SC) phenotype and genotype may reflect either plasticity or heterogeneity, which was difficult to evaluate dynamically until the achievement of long-term SC expansion. Therefore, we developed six defined culture conditions allowing for the expansion of SC defined by their phenotype and monoclonality in four of seven SS cases. Engraftment of SC through the intrafemoral route into immunodeficient NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ (NSG) mice was achieved in 2 of 14 SS cases. Secondary xenograft by percutaneous injection mimicked most of the features of SS with dermal infiltration, epidermotropism, and blood spreading. These models also allowed assessing the intra-individual heterogeneity of patient SC. Subclones sharing the same TCR gene rearrangement evolved independently according to culture conditions and/or after xenografting. This clonal selection was associated with some immunophenotypic plasticity and limited genomic evolution both in vitro and in vivo. The long-term amplification of SC allowed us to develop eight new SC lines derived from four different patients. These lines represent the cell of origin diversity of SC and provide new tools to evaluate their functional hallmarks and response to therapy.
- 1 November 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (11) , 2334-2342.e8
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type
- 1 November 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (11) , 2334-2342.e8
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 248
La cellule de Sézary : une nouvelle définition phénotypique et moléculaire
- 1 December 2017
- Published by Elsevier in Morphologie
- Vol. 101 (335) , 248
La cellule de Sézary : une nouvelle définition phénotypique et moléculaire
- Open Access
Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene
Neurofibromatosis 1 (NF1) is one of the most common genetic disorders and is caused by mutations in the NF1 gene. NF1 gene mutational analysis presents a considerable challenge because of its large size, existence of highly homologous pseudogenes located throughout the human genome, absence of mutational hotspots, and diversity of mutations types, including deep intronic splicing mutations. We aimed to evaluate the use of hybridization capture-based next-generation sequencing to screen coding and noncoding NF1 regions. Hybridization capture-based next-generation sequencing, with genomic DNA as starting material, was used to sequence the whole NF1 gene (exons and introns) from 11 unrelated individuals and 1 relative, who all had NF1. All of them met the NF1 clinical diagnostic criteria. We showed a mutation detection rate of 91% (10 out of 11). We identified eight recurrent and two novel mutations, which were all confirmed by Sanger methodology. In the Sanger sequencing confirmation, we also included another three relatives with NF1. Splicing alterations accounted for 50% of the mutations. One of them was caused by a deep intronic mutation (c.1260 + 1604A > G). Frameshift truncation and missense mutations corresponded to 30% and 20% of the pathogenic variants, respectively. In conclusion, we show the use of a simple and fast approach to screen, at once, the entire NF1 gene (exons and introns) for different types of pathogenic variations, including the deep intronic splicing mutations.
Open AccessHybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene
Neurofibromatosis 1 (NF1) is one of the most common genetic disorders and is caused by mutations in the NF1 gene. NF1 gene mutational analysis presents a considerable challenge because of its large size, existence of highly homologous pseudogenes located throughout the human genome, absence of mutational hotspots, and diversity of mutations types, including deep intronic splicing mutations. We aimed to evaluate the use of hybridization capture-based next-generation sequencing to screen coding and noncoding NF1 regions. Hybridization capture-based next-generation sequencing, with genomic DNA as starting material, was used to sequence the whole NF1 gene (exons and introns) from 11 unrelated individuals and 1 relative, who all had NF1. All of them met the NF1 clinical diagnostic criteria. We showed a mutation detection rate of 91% (10 out of 11). We identified eight recurrent and two novel mutations, which were all confirmed by Sanger methodology. In the Sanger sequencing confirmation, we also included another three relatives with NF1. Splicing alterations accounted for 50% of the mutations. One of them was caused by a deep intronic mutation (c.1260 + 1604A > G). Frameshift truncation and missense mutations corresponded to 30% and 20% of the pathogenic variants, respectively. In conclusion, we show the use of a simple and fast approach to screen, at once, the entire NF1 gene (exons and introns) for different types of pathogenic variations, including the deep intronic splicing mutations.